Initial Pushita results encouraging:
This article was originally published in Clinica
The results of the first phase of MicroSense International's human feedback trial of its Pushita blood glucose monitor (see Clinica No 913, p 17) have shown less than 5% variation when compared with "the leading blood glucose monitor". Pushita measures the concentration of glucose in interstitial fluid, rather than blood, which means that sampling is less painful for the patient. MicroSense's objective now is to complete the trial and find a strategic partner to bring the product to market.
You may also be interested in...
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.
The FDA has released final guidance on “Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA” for the industry. The guidance brings clarity and aims at facilitating product development meetings between the FDA and the ANDA applicants for complex products.
By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.